AAN PREVIEW: Oral drugs make a case for surpassing biologics in MS
This article was originally published in Scrip
Executive Summary
Oral drugs may overtake biologics as the multiple sclerosis market leaders, but biological therapies will maintain significant market share as new monoclonal antibodies emerge to unseat MS mainstays, such as Biogen Idec's Tysabri (natalizumab).